ArticleInfection and immunity2008
Role of NleH, a type III secreted effector from attaching and effacing pathogens, in colonization of the bovine, ovine, and murine gut.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Cell Death and Infection: Implications for Host and Microbe.Advances in experimental medicine and biology · 2025Review
- Effect of Propionate on Citrobacter rodentium Infection in Mice by Regulating NleH Expression.Journal of cellular and molecular medicine · 2024Article
- Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence.Nature microbiology · 2024Article
- Taming the Beast: Interplay between Gut Small Molecules and Enteric Pathogens.Infection and immunity · 2019Review
- Bacterial Chat: Intestinal Metabolites and Signals in Host-Microbiota-Pathogen Interactions.Infection and immunity · 2017Review
- Virulence factors of Shiga toxin-producing Escherichia coli and the risk of developing haemolytic uraemic syndrome in Norway, 1992-2013.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Article
- Bacterial effector NleL promotes enterohemorrhagic E. coli-induced attaching and effacing lesions by ubiquitylating and inactivating JNK.PLoS pathogens · 2017Article
- Citrobacter rodentium mouse model of bacterial infection.Nature protocols · 2016Article
- Article
- A distinct regulatory sequence is essential for the expression of a subset of nle genes in attaching and effacing Escherichia coli.Journal of bacteriology · 2012Article
- Functional differences and interactions between the Escherichia coli type III secretion system effectors NleH1 and NleH2.Infection and immunity · 2012Article
- Expression and regulation of the Escherichia coli O157:H7 effector proteins NleH1 and NleH2.PloS one · 2012Article
- Enterohemorrhagic E. coli (EHEC) pathogenesis.Frontiers in cellular and infection microbiology · 2012Review
- Noninvasive biophotonic imaging for studies of infectious disease.FEMS microbiology reviews · 2011Review
- Binding to Na(+) /H(+) exchanger regulatory factor 2 (NHERF2) affects trafficking and function of the enteropathogenic Escherichia coli type III secretion system effectors Map, EspI and NleH.Cellular microbiology · 2010Article
- Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-κB activation.Molecular microbiology · 2010Article
- Breaking the stereotype: virulence factor-mediated protection of host cells in bacterial pathogenesis.PLoS pathogens · 2010Article
- NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli.Journal of bacteriology · 2010Article
- Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function.PLoS pathogens · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
The human pathogen enterohemorrhagic Escherichia coli (EHEC) O157:H7 colonizes human and animal gut via formation of attaching and effacing lesions. EHEC strains use a type III secretion system to translocate a battery of effector proteins into the mammalian host cell, which subvert diverse signal transduction pathways implicated in actin dynamics, phagocytosis, and innate immunity. The genomes of sequenced EHEC O157:H7 strains contain two copies of the effector protein gene nleH, which share 49% sequence similarity with the gene for the Shigella effector OspG, recently implicated in inhibition of migration of the transcriptional regulator NF-kappaB to the nucleus. In this study we investigated the role of NleH during EHEC O157:H7 infection of calves and lambs. We found that while EHEC DeltanleH colonized the bovine gut more efficiently than the wild-type strain, in lambs the wild-type strain exhibited a competitive advantage over the mutant during mixed infection. Using the mouse pathogen Citrobacter rodentium, which shares many virulence factors with EHEC O157:H7, including NleH, we observed that the wild-type strain exhibited a competitive advantage over the mutant during mixed infection. We found no measurable differences in T-cell infiltration or hyperplasia in colons of mice inoculated with the wild-type or the nleH mutant strain. Using NF-kappaB reporter mice carrying a transgene containing a luciferase reporter driven by three NF-kappaB response elements, we found that NleH causes an increase in NF-kappaB activity in the colonic mucosa. Consistent with this, we found that the nleH mutant triggered a significantly lower tumor necrosis factor alpha response than the wild-type strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.